Oncology

Top news of the week in oncology and cancer drug development.

Rates of suicide elevated in cancer survivors diagnosed before the age of 25 years.

The biosimilar epoetin was well-tolerated in elderly cancer patient populations.

Xtandi plus abiraterone acetate and prednisone fails to improve progression-free survival in prostate cancer.

Ceritinib (Zykadia) could potentially be used as a first-line treatment in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.

Attacking lung cancer cell foundation may present effective treatment option.

New findings may lead to therapeutic options for stopping lung cancer cells from spreading to different parts of the body.

Sofosbuvir/ribavirin treatment is typically prescribed for 12 weeks, but for some patients with hepatitis C virus, a longer duration may be needed.

Zykadia more than doubled progression-free survival in patients with ALK+ non-small cell lung cancer.

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Alcohol could cause 7100 annual cancer deaths by 2035.

Blood test helps predict how aggressive lung cancer patients will respond to treatment.

Top news of the day from across the health care landscape.

Switching Tasigna elicited a long-term response rate in patients with leukemia even after discontinuing treatment.

Lenalidomide (Revlimid) could potentially offer clinical benefits to patients with multiple myeloma.

A newly created tool can diagnose cachexia in patients with cancer and other diseases.

Interim findings further support the efficacy, safety, and tolerability of Abraxane in NSCLC.

Abraxane shows promise in hard-to-treat non-small cell lung cancer patients.

A PGY-2 Oncology Residency Director shares her advice for residents about remaining adaptable.

Individuals with a history of cigarette smoking may benefit from regular ibuprofen use.

Top news of the day from across the health care landscape.

Once-daily tablet for hepatitis C virus contains sofosbuvir, velpatasvir, and voxilaprevir.

Checkpoint inhibitor resistance remains an issue in cancer therapy.

Top news of the week in oncology and cancer drug development.

A Memorial Sloan-Kettering pharmacist discusses the often complicated reimbursement process for oncology medications and appeals.

A hematology/oncology clinical pharmacist with Memorial Sloan-Kettering Cancer Center discusses the importance of early collaboration between pharmacists and oncologists in patient care.

Inhibiting communication between proteins and the Golgi apparatus could possibly prevent lung cancer metastasis.